APZANRI
Live / Applied — Second extension granted (statement of use) (as of 11 Feb 2025)
What this means for you
Not registered yet, but its 19 Dec 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98322465
- Mark type
- Stylized text
- Filed
- 19 Dec 2023
- Published for opposition
- 16 Jul 2024
- Attorney of record
- Heather A. McDonald
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 12 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Feb 2025 — SOU EXTENSION 2 GRANTED
- 11 Feb 2025 — SOU EXTENSION 2 FILED
- 11 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2025 — SOU EXTENSION 1 GRANTED
- 11 Feb 2025 — SOU EXTENSION 1 FILED
- 11 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Sept 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Jul 2024 — PUBLISHED FOR OPPOSITION
- 16 Jul 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Jul 2024 — PUBLISHED FOR OPPOSITION
- 26 Jun 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 Jun 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER